Insider Buying: Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Buys 15,816 Shares of Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Robert Christopher Andrade purchased 15,816 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was acquired at an average cost of C$3.43 per share, for a total transaction of C$54,248.88.

Fennec Pharmaceuticals Stock Down 0.5 %

Shares of FRX stock traded down C$0.03 during trading on Thursday, reaching C$6.47. The company’s stock had a trading volume of 2,037 shares, compared to its average volume of 1,869. Fennec Pharmaceuticals Inc. has a 1-year low of C$5.65 and a 1-year high of C$15.43. The stock’s 50-day moving average price is C$6.40 and its 200 day moving average price is C$7.99. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. The company has a market capitalization of C$177.02 million, a price-to-earnings ratio of 65.00 and a beta of 0.25.

Wall Street Analysts Forecast Growth

Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.